Cue Biopharma (NASDAQ:CUE) Releases Quarterly Earnings Results, Misses Expectations By $22.45 EPS

Cue Biopharma (NASDAQ:CUE) posted its earnings results on Friday. The company reported ($24.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45), FiscalAI reports. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million.

Cue Biopharma Price Performance

Shares of Cue Biopharma stock traded up $3.12 on Friday, reaching $34.20. The company had a trading volume of 157,074 shares, compared to its average volume of 195,652. The firm’s 50-day moving average price is $29.50 and its two-hundred day moving average price is $147.28. Cue Biopharma has a 1 year low of $4.97 and a 1 year high of $45.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CUE. Northwestern Mutual Wealth Management Co. increased its position in Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after acquiring an additional 73,000 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of Cue Biopharma in the 3rd quarter worth about $62,000. Stifel Financial Corp boosted its stake in shares of Cue Biopharma by 25.4% during the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the period. Finally, Boothbay Fund Management LLC boosted its stake in shares of Cue Biopharma by 15.3% during the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares during the period. 35.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CUE has been the topic of a number of recent research reports. Weiss Ratings raised shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen upgraded shares of Cue Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cue Biopharma presently has a consensus rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.